Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Protocol
  • Published:

High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR)

Abstract

Integrating vector systems used in clinical gene therapy have proven their therapeutic potential in the long-term correction of immunodeficiencies1,2,3,4. The integration loci of such vectors in the cellular genome represent a molecular marker unique for each transduced cell and its clonal progeny. To gain insight into the physiology of gene-modified hematopoietic repopulation and vector-related influences on clonal contributions, we have previously introduced a technology—linear amplification–mediated (LAM) PCR—for detecting and sequencing unknown DNA flanking sequences down to the single cell level5 (Supplementary Note online). LAM-PCR analyses have enabled qualitative and quantitative measurements of the clonal kinetics of hematopoietic regeneration in gene transfer studies, and uncovered the clonal derivation of non-leukemogenic and leukemogenic insertional side effects in preclinical and clinical gene therapy studies4,6,7,8. The reliability and robustness of this method results from the initial preamplification of the vector-genome junctions preceding nontarget DNA removal via magnetic selection. Subsequent steps are carried out on a semisolid streptavidin phase, including synthesis of double complementary strands, restriction digest, ligation of a linker cassette onto the genomic end of the fragment and exponential PCR(s) with vector- and linker cassette–specific primers. LAM-PCR can be adjusted to all unknown DNA sequences adjacent to a known DNA sequence. Here we describe the use of LAM-PCR analyses to identify 5′ long terminal repeat (LTR) retroviral vector adjacent genomic sequences (Fig. 1 and Box 1).

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic outline of LAM-PCR to amplify 5′-LTR retroviral vector-genomic fusion sequences.
Figure 2: LAM-PCR analysis of clinical samples.

Similar content being viewed by others

References

  1. Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669–672 (2000).

    Article  CAS  Google Scholar 

  2. Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413 (2002).

    Article  CAS  Google Scholar 

  3. Gaspar, H.B. et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181–2187 (2004).

    Article  CAS  Google Scholar 

  4. Ott, M.G. et al. Correction of X-linked chronic granulomatous disease by gene therapy is augmented by insertional activation of MDS/EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401–409 (2006).

    Article  CAS  Google Scholar 

  5. Schmidt, M. et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 100, 2737–2743 (2002).

    Article  CAS  Google Scholar 

  6. Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003).

    Article  CAS  Google Scholar 

  7. Deichmann, A. et al. Vector integration is non-random, clustered and influences the in vivo fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117, 2225–2232 (2007).

    Article  CAS  Google Scholar 

  8. Schwarzwaelder, K. et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest. 117, 2241–2249 (2007).

    Article  CAS  Google Scholar 

  9. Mueller, P.R. & Wold, B. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science 246, 780–786 (1989).

    Article  CAS  Google Scholar 

  10. Glimm, H. et al. Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. Blood 106, 893–898 (2005).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft, the German Ministry of Education and Research, the European Union and the US National Institutes of Health. We thank all present and former members and collaborators of our laboratory who have contributed work or materials to the many experiments, time and efforts toward establishing and optimizing this protocol.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Manfred Schmidt or Christof von Kalle.

Ethics declarations

Competing interests

LAM-PCR is filed as a US patent 6514706 that is licensed to Cinciannati Childrens Hospital Medical Center (CCHMC), USA.

Supplementary information

Supplementary Table, Methods and Note

Supplementary Tables 1–2, Supplementary Methods, Supplementary Note (PDF 201 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, M., Schwarzwaelder, K., Bartholomae, C. et al. High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR). Nat Methods 4, 1051–1057 (2007). https://doi.org/10.1038/nmeth1103

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nmeth1103

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing